Clinical evaluation of allogeneic adipose tissue-derived stem cells for the treatment of osteoarthritis secondary to hip dysplasia in dogs

ABSTRACT: This study assessed the efficacy of an intra-articular injection of allogeneic adipose tissue-derived from mesenchymal stem cells (AD-MSCs) for the treatment of hip dysplasia in dogs. The study group included 12 otherwise healthy dogs of different breeds, ages, weights, and degrees of hip dysplasia diagnosed using radiography. An orthopedic assessment was performed on all dogs before and at 30, 60, and 90 days after infusion of AD-MSCs(2 × 106cells). On the same days, each dog’s owner answered a questionnaire based on theHelsinkiChronic Pain Index. The data were converted to ordinal data based on the score for each variable, and the Friedman test for multiple comparisons was used to verify the results. Compared with the corresponding values on day 0, orthopedic and gait assessments and owners’ reported pain indexes improved over the 90-day observation period. These results suggested that treatment with allogeneic AD-MSCs significantly reduced the clinical signs associated with hip dysplasia during the study period. However, long-term studies are needed to determine the optimal therapeutic protocol for routine clinical use of AD-MSCs in hip dysplasia.

摘要：本研究评估了关节腔内注射异体脂肪来源间充质干细胞（adipose tissue-derived mesenchymal stem cells，AD-MSCs）治疗犬髋关节发育不良的疗效。本研究纳入12只除髋关节发育不良外其余均健康的犬，其品种、年龄、体重及髋关节发育不良程度均存在差异，所有受试犬均通过X线摄影确诊该病。在受试犬接受AD-MSCs（2×10⁶个细胞）输注前，以及输注后第30、60、90天时，均对其进行骨科评估；在上述相同时间点，每只犬的主人均完成基于赫尔辛基慢性疼痛指数（Helsinki Chronic Pain Index）的问卷调研。研究人员根据各变量的评分将原始数据转换为有序分类数据，并采用用于多重比较的弗里德曼检验（Friedman test）对结果进行验证。与第0天的对应指标相比，在90天的观察期内，受试犬的骨科与步态评估结果以及主人报告的疼痛指数均得到改善。上述结果表明，在本研究周期内，异体AD-MSCs治疗可显著缓解犬髋关节发育不良相关的临床症状。但仍需开展长期研究，以确定AD-MSCs用于犬髋关节发育不良常规临床治疗的最佳方案。